UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2022

CLEARPOINT NEURO, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-34822 (Commission File Number) 58-2394628 (I.R.S. Employer Identification Number)

120 S. Sierra Ave., Suite 100 Solana Beach, CA 92075 (Address of principal executive offices, zip code)

(888) 287-9109

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 9, 2022, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its financial performance for the second fiscal quarter ended June 30, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On August 9, 2022, the Company posted an updated investor presentation to its website at http://ir.stockpr.com/clearpointneuro/investor-presentations. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

- Exhibit 99.1 Press Release dated August 9, 2022
- Exhibit 99.2 Investor Presentation dated August 9, 2022
- Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 9, 2022

CLEARPOINT NEURO, INC.

By: /s/ Danilo D'Alessandro Danilo D'Alessandro

Chief Financial Officer



ClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

SOLANA BEACH, CA, August 9, 2022 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022.

Second Quarter Highlights

- Reported record quarterly revenue of \$5.2 million, a 52% year-over-year increase;
- Partner PTC Therapeutics received a positive opinion for its gene therapy treatment Upstaza^{TM.} from the European Medicines Agency's Committee for Medicinal Products for Human Use. Upstaza, which was granted full marketing authorization by the European Commission in July 2022, will be administered with the Company's SmartFlow[®] Neuro Cannula;
- Increased biologics and drug delivery revenue to \$2.4 million, a 73% year-over-year increase;
- Added multiple new biologics and drug delivery partners in the quarter to bring the total to more than 45;
- Installed four additional systems in the quarter bringing the total to 8 new installations year-to-date;
- Achieved Medical Device Single Audit Program (MDSAP) certification paving the way for additional international regulatory submissions in support of pharmaceutical partners; and
- Cash and short-term investments totaled \$45.1 million as of June 30, 2022.

Business Outlook

• The Company reaffirms its full year 2022 revenue outlook of between \$21.0 and \$22.0 million.

"The ClearPoint Neuro Team has continued to execute against our four-pillar growth strategy in the second quarter," commented Joe Burnett, President and CEO. "We achieved another record quarter for revenue and over 50% growth despite an elevated case cancellation rate and supply chain disruptions. Our biologics and drug delivery business led the way and became our largest segment with product and service revenue growing at more than 70%. The team also added multiple new pharma and academic partners bringing our total to more than 45 and keeping pace at approximately one new partner each month. Our ClearPoint Navigation system was installed at four additional centers bringing the total new centers to eight in 2022 across the U.S. and Europe. Our product development team continues to execute on our pipeline and has additional products being reviewed by global regulatory bodies.

Particularly of note, the European Commission granted marketing authorization for Upstaza to our partner PTC Therapeutics. Upstaza is the first gene therapy approved anywhere in the world to be dosed by direct infusion into the brain. Consistent with our long term strategy, the Summary of Product Characteristics for Upstaza specifically includes the ClearPoint SmartFlow Neuro Cannula as the device used for minimally invasive infusion of the gene therapy. We believe the approval of Upstaza, delivered with ClearPoint's cannula, demonstrates the viability and potential of our drug delivery partnerships.

At present, we are reaffirming our prior guidance of revenue between \$21.0 and \$22.0 million for the year."

Financial Results – Quarter Ended June 30, 2022

Total revenue was \$5.2 million for the three months ended June 30, 2022, and \$3.4 million for the three months ended June 30, 2021, which represents an increase of \$1.8 million, or 52%.

Functional neurosurgery navigation and therapy revenue, increased 17% to \$2.2 million for the three months ended June 30, 2022, from \$1.9 million for the same period in 2021. The growth was driven by higher service revenue.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 73% to \$2.4 million for the three months ended June 30, 2022, from \$1.4 million for the same period in 2021. This increase is attributable to a \$0.8 million increase in product revenue and \$0.2 million increase in service revenue.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 282% to \$0.6 million for the three months ended June 30, 2022, from \$0.2 million for the same period in 2021 due to an increase in the sale of ClearPoint systems.

Gross margin for the three months ended June 30, 2022, was 63%, as compared to a gross margin of 67%, for the three months ended June 30, 2021. The decrease in gross margin was due primarily to an increase in overhead expenses, excess and obsolete reserves, and product mix.

Operating expenses for the second quarter of 2022 were \$7.5 million, compared to \$5.7 million for the second quarter of 2021. The increase was mainly driven by the increase in headcount across the organization, product development expenses and share based compensation.

At June 30, 2022, the Company had cash and cash equivalents and short-term investments totaling \$45.1 million as compared to \$54.1 million at December 31, 2021, with the decrease resulting primarily from the use of cash in operating activities of \$9.3 million.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 second quarter on Tuesday, August 9, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=LzXg7k1V. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 437-3179, or at (404) 267-0369 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until September 9, 2022, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.

About ClearPoint Neuro

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint[®] Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with more than 45 pharmaceutical and biotech companies, academic institutions, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the

Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forwardlooking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2022, which the Company intends to file with the Securities and Exchange Commission on or before August 15, 2022.

Contact:

Danilo D'Alessandro, Chief Financial Officer

(949) 900-6833

info@clearpointneuro.com

Caroline Corner, Investor Relations

ir@clearpointneuro.com

CLEARPOINT NEURO, INC. Consolidated Statements of Operations (Unaudited) (Dollars in thousands, except for per share data)

		For The Three Months Ended June 30,	
	2022	2021	
Revenue:			
Product revenue	\$ 3,457	\$ 2,363	
Service and other revenue	1,743	1,050	
Total revenue	5,200	3,413	
Cost of revenue	1,943	1,139	
Gross profit	3,257	2,274	
Research and development costs	2,284	2,109	
Sales and marketing expenses	2,187	1,590	
General and administrative expenses	2,990	1,982	
Operating loss	(4,204)	(3,407)	
Other expense:			
Other expense, net	(8)	(96)	
Interest expense, net	(91)	(240)	
Net loss	\$ (4,303)	\$ (3,743)	
Net loss per share attributable to common stockholders:			
Basic and diluted	\$ (0.18)	\$ (0.17)	
Weighted average shares used in computing net loss per share:			
Basic and diluted	23,985,577	21,523,393	

		For The Six Months Ended June 30,	
	2022	2021	
Revenue:			
Product revenue	\$ 6,620	\$ 5,525	
Service and other revenue	3,611	1,918	
Total revenue	10,231	7,443	
Cost of revenue	3,728	2,555	
Gross profit	6,503	4,888	
Research and development costs	4,817	3,673	
Sales and marketing expenses	4,032	3,165	
General and administrative expenses	5,722	3,638	
Operating loss	(8,068) (5,588)	
Other expense:			
Other income (expense), net	3	(122)	
Interest expense, net	(197) (571)	
Net loss	\$ (8,262	\$ (6,281)	
Net loss per share attributable to common stockholders:			
Basic and diluted	\$ (0.35	\$ (0.31)	
Weighted average shares used in computing net loss per share:			
Basic and diluted	23,834,847	20,195,488	

CLEARPOINT NEURO, INC. Consolidated Balance Sheets (Dollars in thousands, except for per share data)

		June 30, 2022 (Unaudited)		December 31, 2021
ASSETS				
Current assets:				
Cash and cash equivalents	\$	23,524	\$	54,109
Short-term investments		21,613		
Accounts receivable, net		3,348		2,337
Inventory, net		6,639		4,938
Prepaid expenses and other current assets	_	1,517		508
Total current assets		56,641		61,892
Property and equipment, net		689		539
Operating lease rights of use		1,992		2,241
Software license inventory		504		519
Licensing rights		320		265
Other assets		94		125
Total assets	\$	60,240	\$	65,581
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
	\$	1,592	¢	427
Accounts payable	\$,	\$	
Accrued compensation Other accrued liabilities		1,814 870		2,604 537
Operating lease liabilities, current portion		532		507
Deferred product and service revenue, current portion		675		678
Total current liabilities		5,483		4,753 1,939
Operating lease liabilities, net of current portion		1,671 401		264
Deferred product and service revenue, net of current portion		9,865		9,838
2020 senior secured convertible notes payable, net Total liabilities		,		- ,
		17,420		16,794
Commitments and contingencies				
Stockholders' equity: Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at June 30, 2022 and				
December 31, 2021		_		_
Common stock, \$0.01 par value; 200,000,000 shares authorized; 24,480,600 shares issued and outstanding at June 30, 2022 and 23,665,991 issued and outstanding at December 31, 2021	;	245		237
Additional paid-in capital		184,769		182,482
Accumulated deficit		(142,194)		(133,932)
Total stockholders' equity		42,820		48,787
Total liabilities and stockholders' equity	\$	60,240	\$	65,581

CLEARPOINT NEURO, INC. Consolidated Statements of Cash Flows (Unaudited) (Dollars in thousands)

	For	For The Six Months Ended June 30,	
	2022		2021
Cash flows from operating activities:			
Net loss	\$	(8,262) \$	(6,281)
Adjustments to reconcile net loss to net cash flows from operating activities:			
Allowance for doubtful accounts		(10)	92
Depreciation and amortization		187	62
Share-based compensation		1,779	567
Payment-in-kind interest		—	189
Amortization of debt issuance costs and original issue discounts		27	54
Amortization of lease rights of use, net of accretion in lease liabilities		267	267
Accretion of discounts on short-term investments		(23)	_
Increase (decrease) in cash resulting from changes in:			
Accounts receivable		(1,001)	(617)
Inventory, net		(1,786)	(304)
Prepaid expenses and other current assets		(1,010)	(760)
Other assets		30	(93)
Accounts payable and accrued expenses		679	1,312
Lease liabilities		(261)	(195)
Deferred revenue		134	(142)
Net cash flows from operating activities		(9,250)	(5,849)
Cash flows from investing activities:			
Purchases of property and equipment		(145)	(5)
Acquisition of licensing rights		(116)	—
Purchase of short-term investments	((21,590)	—
Net cash flows from investing activities		(21,851)	(5)
Cash flows from financing activities:			
Proceeds from public offering of common stock, net of offering costs		—	46,785
Proceeds from stock option and warrant exercises		256	494
Proceeds from issuance of common stock under employee stock purchase plan		260	
Net cash flows from financing activities		516	47,279
Net change in cash and cash equivalents	((30,585)	41,425
Cash and cash equivalents, beginning of period		54,109	20,099
Cash and cash equivalents, end of period	\$	23,524 \$	61,524
SUPPLEMENTAL CASH FLOW INFORMATION			
Cash paid for:			
Income taxes	\$	— \$	_
income taxes	φ		

Interest

207 \$

353

\$



WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY.


Nasdaq: CLPT

August 2022

Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2022, which the Company intends to file with the Securities and Exchange Commission on or before August 15, 2022.




Our Company ClearPoint Neuro: <u>Two</u> Opportunities, <u>One</u> Platform





- A Common Installed Base Platform and Clinical Specialist Support team
- 35 Active Indications totaling more than 1 million patients diagnosed annually
- A \$12B+ Potential Total Addressable Market



1) A Biologics & Drug Delivery Enabling Company with;


- A unique portfolio of Navigation Tools, Infusion Cannulas, Pre-Clinical and Clinical Services
- More than 45 active pharma/biotech, academic and contract research organization partners

(2) A Neuro Navigation and Device Company with;

- A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation
- · An expanding global installed base of more than 60 centers



Our Company ClearPoint Neuro: A Proven Platform



Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance

PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible







Video source: https://www.youtube.com/watch?v=PsL9B7ftbG4



Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible



© 2022 CLEARPOINT NEURO

5

Our Platform – Procedure Overview The ClearPoint® Neuro Navigation System

26-Sep-1411:00:10 A VL: 9.001:4.028 Anon2014-09-26_07-00 26-Sep-1411.00:10 AM ML: 9,001;4,028




Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.



Our Platform

SmartFrame® XG





SmartFrame XG Trajectory Tower with ClearPoint 2.0 Software CLEARPOINT *Software and Robotic System are currently under development.

SmartFrame Array™






SmartFrame Array Tower with "virtual array" Software and next generation robotic system with increased automation and enabling software*

ClearPoint plans to translate more than 10 years of experience and over 5,000 cases performed in the complex MRI suite into unique and competitive products for the Operating Room

Our Platform


The ClearPoint 'Maestro' Brain Model* Licensed and Jointly Developed with Philips

- 1. Shape Constrained, triangular mesh model enables pointbased correspondence across multiple subjects.
- 2. Fast and capable of peri-procedural imaging without CPU acceleration.
- This model is the basis for future navigation tools, for both the MRI suite and OR, across Biologics & Drug Delivery, DBS Navigation, Brain Computer Interface, Laser Ablation and more.





*The ClearPoint Maestro[™] Brain Model is 510(k) cleared



Broad and Growing User Base of Leading Neurosurgery Centers 60+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco **Stanford University** Lucile Packard Children's Hospital **Benioff Children's Hospital** Sah Francisco VA **USC Keck Hospital** UC San Diego Mayo Clinic in Arizona University of Colorado University of Utah Cook Children's Hospital Texas Children's Hospital **MD** Anderson Cancer Center Houston Methodist Hospital Univ. Kansas Medical Center Dallas Presbyterian Hospital Cincinnati Jewish Children's National Banner Health Tucson **Ohio State University** University of Oklahoma Medical Center Methodist Hospital San Antonio **Barnes-Jewish Hospital Froedtert Hospital**

University of Wisconsin University of Michigan University of Minnesota Cleveland Clinic Northwestern Central DuPage Nationwide Children's Le Bonheur INOVA Fairfax Cincinnati Children's Hospital Charles River Labs – Laval Charles River Labs – Mattawan Children's Mercy Hospital CHOA Scottish Rite Carilion Clinic UPMC Hos. Univ. of Pennsylvania Children's Hospital of Alabama Emory University


100+ Centers Expected by 2025


Rigshospitalet (Copenhagen, Denmark) Mazowiecki Szpital Bródnowski (Warsaw, Poland) Hôpital Fondation Rothschild (Paris, France) Skånes Universitetssjukhus Lund (Lund, Sweden) University Hospital of Wales (United Kingdom) Universitätsklinikum Düsseldorf (Düsseldorf, Germany) Policlinico Umberto I (Rome, Italy) Mt. Sinai West Yale University Weill Cornell **Johns Hopkins University Boston Children's Hospital** Massachusetts General Hospital **Brigham & Women's** Duke University National Institutes of Health Memorial Sloan-Kettering Dartmouth-Hitchcock **Beth Israel Deaconess** Children's Hospital of Philadelphia Hackensack Univ. Med. Center **University of Virginia** Tampa General Hospital Mayo Clinic in Florida

Our MRI-guided therapy platform is currently being used to...



2013 - 2022 Growth in Case Volume and Revenue





© 2022 CLEARPOINT NEURO 11

Expected FY22 Revenue

\$22

\$21


Indication	atient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Ablation	Incremental Revenu from Annual Incidence
Parkinson's Disease	1,000,0001	60,000 ¹	00			\$270 M - \$1.35 B
Drug Resistant Epilepsy	1,000,000 ²	11,000 ³	00			\$49.5 M - \$198 M
Refractory Essential Tremor	3,500,000 ⁴	60,000 ⁵			0	\$180 M - \$1.08 B
Brain Tumors (n=3) ⁶	35,000 ^{7,8}	13,300 ^{7,8}	00		•	\$33.3 M - \$300 M
Severe Obsessive-Compulsive Disorder	500,0009,10	10,0009,10				\$45 M - \$75 M
Dystonia	250,00011	8,000 ¹²				\$36 M - \$60 M
Rare Genetic/Lysosomal (n=7) ¹³	36,50014-18	3,000 ^{14,19,20}	00			\$13.5 M - \$67.5 M
Paralysis / Spinal Cord (n=15) ^{21,22}	331,000 ²²⁻²⁴	17,90023	00	0		\$80.6 M - \$403 M
Huntington's Disease	30,000 ²⁵	4,000 ²⁵	00	0		\$18 M - \$90 M
Auditory Nerve Implant	1,867,00026,27	7,000 ^{26,27}		0		\$31.5 M - \$63 M
Alzheimer's Disease	6,000,000 ²⁸	500,000 ²⁸	00	0		\$1.5 B - \$11.3 B
Severe Major Depressive Disorder	1,000,00010	20,000 ^{10,29}		0		\$90 M - \$150 M
Stroke Rehabilitation	2,000,000 ³⁰	610,000 ³⁰		0		\$1.83 B - \$5.49 B
Frontotemporal Dementia	60,000 ³¹	12,00031	0			\$54 M – \$270 M
rontotemporar bententia						64 3 D 630 0 D
ronocenpora benenia						\$4.2 B - \$20.8 B

ClearPoint Neuro Market Opportunity – United States Citations & Footnotes

- 1. "Parkinson's Disease Statistics," Parkinson's News Today, https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#.":text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older
- Neurona Therapeutics. (2021 November 4). Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients [Press release] https://www.neuronatherapeutics.com/wp-content/uploads/2021/11/2021_11_01_-INDClearance_FINALVersion.pdf
- 3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. World Neurosurg. 2017;99:662-666.
- 4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. Neuropsychiatr Dis Treat. 2010;6:401-408. Published 2010 Sep 7.
- 5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. Parkinsonism Relat Disord. 2010;16(9):604-607.
- 6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
- 7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
- 8. "About DIPG/DMG," DIPG/DMG Registry, https://dipgregistry.org/patients-families/about-dipg-dmg/
- 9. Medtronic Clinical Summary Reclaim DBS for Chronic Extreme OCD M947128A001.
- 10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. Anxiety Disorders: Theory, Research and Clinical Perspectives. Cambridge: Cambridge University Press; 2010:323-335.
- 11. https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia
- 12. Medtronic DBS[™] Therapy for Dystonia Clinical Summary 2015.
- 13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
- 14. "Multiple System Atrophy," Medscape, https://emedicine.medscape.com/article/1154583-overview#a6
- 15. PTC Therapeutics November 30, 2021 Corporate Presentation, https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45
- 16. "Spinocerebellar ataxia type 3," Orphanet, https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757
- 17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation final.pdf
- 18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/
- 19. "Aromatic L'Amino Acid Decarboxylase Deficiency," National Organization for Rare Disorders, https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/
- 20. Puckett Y, Mallorga-Hernández A, Montaño AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16(1):241. Published 2021 May 29.
- 21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
- 22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. Am J Public Health. 2016;106(10):1855-1857.
- 23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. Spinal Cord. 2006;44(9):523-529.
- 24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. https://www.nscisc.uab.edu/
- 25. "Huntington's Disease," Mov Disord. 2019 Jun; 34(6): 858-865.
- 26. "Cochlear Implants," National Institute on Deafness and Other Communication Disorders, https://www.nidcd.nih.gov/health/cochlear-implants
- 27. "Cochlear Implant Surgery," Medscape, https://emedicine.medscape.com/article/857242-overview
- 28. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures
- 29. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. Annu Rev Med. 2012;63:511-524.
- 30. "Stroke Facts," Center for Disease Control and Prevention, https://www.cdc.gov/stroke/facts.htm
- 31. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25(2):130-137.



Innovation Pipeline ClearPoint Neuro is Dedicated to Innovation in the Neuro Space



New Global Showcase Site ClearPoint Global Training & Innovation Center – Solana Beach, CA

- Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback
- Showcase new technologies to Pharmaceutical and BCI partners
- · Home for Clinical Specialists to support cases remotely without travel







ACHIEVE GLOBAL SCALE

Expand Global Footprint to 100 Centers Open WW Training / Remote Support Facility Launch Robotic Platform into MRI and O.R. Release Digital Health Patient Portal Application

NEW THERAPY DEVICES

Enter the Neuro Laser Ablation Market Launch Maestro Brain Model and Therapy Apps Penetrate 'Access' Markets to Improve Efficiency (Drill) Build the 'Smart' Biopsy Market

a BCI arket lures tions

NEURO NAVIGATION FOR DBS & BCI

Expand into the Operating Room, Enter the MER Market cate Patients on DBS Options including 'Asleep' and 'Awake' Procedures Participate in Trials for new DBS indications Launch surgical solution for Brain-Computer Interfaces (BCI)

BIOLOGICS & DRUG DELIVERY

Expand Translational & Clinical Services Accumulate Additional Global Partners Across Diverse Indications Execute on Development Pipeline for Intracranial and Spinal Routes of Administration Expand Partnership Models to Include Milestone Based Collaborative Agreements

2025

© 2022 CLEARPOINT NEURO 16

4 Pillar Growth Strategy by 2025

Target Indications of > 1,000,000 Patients Diagnosed Each Year Potential Total Addressable Market for CLPT of \$12B+



2022

CLPT Capabilities Executive Summary



Unique platform technology

enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Large, growing installed base in 60+ of 500+ leading Neurosurgery and research centers Worldwide



Pipeline of new revenue streams

from product improvements, biologic and drug delivery partnerships and services, standalone therapy products, and Brain Computer Interface Navigation



Expandable Platform

with realizable synergies beyond the MRI and into the operating room and radiology suite



\$

Total potential addressable market > \$12B for our products, pipeline and partnerships



A growing and passionate team of embedded scientists and specialists

© 2022 CLEARPOINT NEURO

17

CLEARPOINT



